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ABSTRACT 
The protein catalyzed capture (PCC) agent platform provides a new strategy to develop peptide-
based ligands for difficult protein targets. This approach utilizes the target-guided in situ click 
reaction to allow the protein of interest to assemble its own binder. Developing a PCC agent 
begins with an epitope targeting strategy to develop anchor candidates against a specific region 
of interest on the target protein. This approach has been used to target diverse epitopes including 
unstructured hydrophobic regions, allosteric enzyme sites, and single amino acid point 
mutations. The process can then be iterated to expand a monoligand into a multiligand binder 
with affinity and selectivity that rivals monoclonal antibodies.  
 
One disease-associated protein of particular importance is the serine/threonine kinase Akt. Akt 
is a key regulator of signal transduction pathways and is implicated in many disease such as 
cancer, diabetes, and neurodegeneration. Several ligands for Akt have been developed recently 
with the PCC agent screening approach. PCC agents now exist that can alter Akt enzymatic 
activity, detect its position in the cell, identify mutations within the protein, and even cause its 
destruction within the cell. The first part of this thesis summarizes the prior efforts to develop 
PCC agents against Akt and then describes new applications for these reagents while the latter 
part describes efforts to develop new PCC agents against another interesting target.  
 
Chapter 1 provides a summary of the technology and describes how it has been utilized thus far. 
Chapter 2 describes how a PCC agent was used as an imaging probe capable of detecting Akt 
membrane localization. Chapter 3 provides several examples of the modularity of PCC agents 
and demonstrates how they can be used to influence a target protein in cells. A pair of allosteric 
 vii 
Akt modulators were functionalized with a cell penetrating peptide for cellular delivery and 
were subsequently used to activate or inhibit Akt enzymatic activity. PCC agents can also be 
used as a targeting moiety to deliver a specific signal to a protein. When functionalized with a 
degradation tag the Akt-binding capture agents caused the protein to be degraded. This provides 
another demonstration of the usefulness of Proteolysis Targeting Chimeric Molecules, or 
PROTACs, in destroying disease-associated proteins. Finally, Chapter 4 describes the 
development of PCC agents against the oncoprotein K-RasG12D and how these molecules can be 
used to target this protein in new ways.  
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C h a p t e r  1  
PROTEIN CATALYZED CAPTURE AGENTS AS AN ALTERNATIVE 
PLATFORM FOR DEVELOPING DIAGNOSTICS AND THERAPEUTIC 
REAGENTS 
1.1 Introduction  
There is a great need to develop high-affinity protein binding reagents. As proteins serve 
as the functional output of the genetic code it is crucial that new ligands are developed to 
advance our basic understanding of biological processes.  Development of such ligands can 
help elucidate protein functions, diagnose disease, and develop novel therapeutics. Such 
efforts are thus necessary to continue advancing the field of personalized medicine. 
 
The current standard reagents for protein binding assays are antibodies.1 Antibodies are 
large, typically 150 kDa, Y-shaped proteins that are normally created by the immune 
system to help combat disease.2 Researchers have used antibodies as tools for studying 
proteins for several decades. Antibodies have also proven useful as diagnostic reagents for 
detecting biomarkers such as human chorionic gonadotropin (hCG) in home pregnancy 
tests or the cancer-associated antigen Prostate-specific antigen (PSA).3 Additionally, 
antibodies are also a very useful class of therapeutic molecules to treat disease. For 
instance, the anti-inflammatory medication Humira is a monoclonal antibody against the 
pro-inflammatory signal TNF alpha and this molecule is used to treat myriad autoimmune 
diseases.4 However, while antibodies have become invaluable tools for basic research, 
diagnostics, and therapeutics, they do have several limitations that include lack of 
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reproducibility, instability, and poor bioavailability. Antibodies often suffer from batch 
to batch variability due to the biological nature of their production.5 They are often 
produced in immunized animals and the same animal will produce multiple antibodies 
against the same antigen. Complicating matters further is the fact that the same animal will 
produce different mixtures of antibodies after each immunization with the same antigen. 
In addition, if an antibody source, whether an animal or cell line, is lost then the 
corresponding antibody will also be difficult to reproduce — because research antibodies 
are often poorly characterized it is more likely that the antibody will be lost forever.6 
Moreover, antibodies can also suffer from instability. As with any protein, antibodies are 
subject to thermal denaturation, aggregation, and proteolytic degradation.7 Therapeutic 
antibodies are also known to be susceptible to oxidation which can abrogate the desired 
binding properties and effectiveness of the treatment.8 Finally, due to their relatively large 
size therapeutic antibodies are thought to be limited to extracellular targets.9 While 
therapeutic antibodies have been very successful against soluble proteins and extracellular 
membrane receptors a large number of important therapeutic targets are intracellular 
proteins that are inaccessible to this type of drug – membrane and secreted proteins only 
account for about one third of the approximately 20,000 proteins in the human proteome.10 
While antibodies are immensely useful for basic research, diagnostics, and therapeutics, 
complementary methods are still needed to develop protein-binding reagents.  
 
 Another useful class of reagents for studying and perturbing protein functions are small 
molecules. Small molecules are low molecular weight (typically <500 daltons) organic 
compounds that often have interesting biological properties. Small molecules are widely 
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used to modulate protein function through either activation or inhibition of the enzymatic 
activity of specific target proteins.11 These compounds can thus have dramatic effects on 
biological systems, depending on the protein target. By enabling the specific activation or 
inhibition of a given target small molecules can be useful probes for elucidating enzyme 
functions in cells.11 In addition, the relatively small size and hydrophobicity of many small 
molecules enable diffusion across biological membranes to reach intracellular targets — 
small molecules thus make up the majority of drugs.12 However, while small molecules 
have been developed against myriad enzymes they are typically limited to this class of 
protein, yet enzymes only represent a small portion of the proteome. They are often 
restricted to binding in small hydrophobic pockets of proteins and these pockets are most 
often found in enzymes where a substrate will bind prior to its transformation. Small 
molecule inhibitors can therefore outcompete the natural substrate for the active site and 
inhibit the enzyme’s catalytic activity.13 It has proven difficult to target non-enzymatic 
disease-associated targets such as transcription factors or protein-protein interactions 
because these proteins often lack hydrophobic pockets for small molecules to bind.14 
Therefore, targeting certain disease-associated targets will require alternative approaches 
to both antibodies and small molecules.  
 
While antibodies and small molecules differ in their chemical properties and uses, one class 
of molecule that can potentially combine the advantageous properties of these two groups 
is peptides.15 Antibodies are very useful because of their relatively high affinity and 
specificity for their corresponding antigen. While antibodies are 150 kDa macromolecules 
only a small portion of the structure is responsible for antigen recognition. The majority of 
  
4 
diversity found in an antibody variable regions is located in the single CDR-H3 loop,16 
and the average size of this loop is 15 amino acid residues17 – peptides thus represent 
promising antibody replacements. Additionally, peptides also have similarities to small 
molecules. The major strength of small molecules (bioavailability) is thought to arise in 
large part from their size and peptides can also be small enough to diffuse into cells and 
tissues. Indeed, over 60 therapeutic peptides have been approved to date with 
approximately 140 additional peptide drugs in clinical trials.18 The recent success of 
peptide medicines demonstrates that these molecules can potentially combine the favorable 
properties of antibodies and small molecules to develop new probes, diagnostics, and 
therapeutic reagents. One emerging class of useful peptides is protein catalyzed capture 
agents, which will be the focus of this thesis.  
 
1.2 Protein Catalyzed Capture Agents 
Protein catalyzed capture (PCC) agent technology is an emerging screening platform that 
enables the identification of high-affinity peptide ligands against a protein of interest. The 
screening approach is based on the iterative in situ click chemistry reaction that allows a 
target of interest to identify its own high-affinity, multiligand binder.  
 
A key component of this screening platform is the in situ click reaction between an azide 
and alkyne. This reaction was first developed by the Sharpless group as a target-guided 
method to identify potent, small molecule enzyme inhibitors.19 In their initial study the 
Sharpless group identified a small molecule inhibitor that could be divided into two 
fragments and each fragment was expanded into a small molecule library – one library was 
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functionalized with an azide and the other with an alkyne. Both libraries were then 
simultaneously incubated with the target protein and only the library elements that bound 
the protein adjacent to one another in the proper orientation could undergo the Huisgen 
1,3-dipolar cycloaddition reaction to create a new inhibitor. The resulting inhibitor was 
more potent than either library element alone. The protein thus serves as a scaffold to 
properly align the molecules and assemble its own “best fit” inhibitor.  
 
In the Heath group at Caltech we have been working to generalize the in situ click screening 
approach and have made several improvements. First, a novel one-bead-one-compound 
macrocyclic peptide library that presents either an azide or alkyne has been developed.20 
The library is easily synthesized via solid phase peptide synthesis using standard methods. 
The synthesis begins by making the linear library consisting of Pra-X1X2X3X4X5-Az4 
(where Pra = Propargylglycine and Az4 = Azidolysine) followed by a copper catalyzed 
azide-alkyne cycloaddition to close the macrocycle through the Pra and Az4 side chains. 
The variable region, X1-X5, is composed of the 18 naturally occurring amino acids 
(excluding Cys and Met) and yields more than 1.8x106 possible sequences. Unnatural 
amino acids can also be incorporated into the library increasing the potential diversity even 
more. The variable region is also sequenceable by Edman degradation. This allows facile 
identification of hit sequences.  
 
Secondly, our PCC agent screening platform utilizes a chemical epitope targeting strategy 
to home in on a specific region of the protein of interest.21, 22 The epitope of interest can be 
chemically synthesized with the addition of a Pra or Az4 click group and a biotin affinity 
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handle. This new synthetic epitope (SynEp) can then be screened against a macrocyclic 
library containing the opposite click group and hit sequences are identified with a 
streptavidin-reporter conjugate. Only the library peptides that bind to the SynEp will 
undergo the click reaction. While most small molecule probes are limited to targeting 
hydrophobic binding pockets, our epitope targeting strategy allows us to potentially target 
any site on a protein surface. Thus far we have targeted unstructured hydrophobic regions,21 
single amino acid point mutations,22 and allosteric enzymatic sites.23  
 
Additionally, a third major advance has been to iterate the in situ click screens to develop 
multiligand binders that are much improved over monoligands.23,24 After the initial epitope 
targeting screen the hit sequences are tested for binding to the full-length protein. After 
multiple rounds of binding assays a consensus sequence, typically called the anchor 
peptide, is chosen to improve upon with subsequent screens. As with the SynEp in the 
anchor screen, the anchor peptide is synthesized with a click group and biotin handle and 
incubated with the target protein in the presence of a library. Similar to the original in situ 
click study, the click reaction is catalyzed by the formation of a ternary complex between 
the anchor peptide, target protein, and the appropriate library element. The hit secondary 
ligands can then be combined with the anchor peptide to provide a series of biligand 
candidates. Typically, the biligands will show increased affinity and selectivity for the 
target protein compared to the anchor peptide. Once a consensus biligand is identified after 
multiple rounds testing the process can be iterated once again to develop a triligand peptide 
with further improved binding properties. These major advances have greatly improved the 
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in situ click screening approach and provide a promising strategy for the development of 
high-affinity protein ligands.  
 
The subsequent chapters of this thesis will describe the development of PCC agents against 
cancer-associated targets and new applications of this technology. One target of particular 
interest is the human protein Akt. Akt is a serine/threonine protein kinase with three closely 
related isoforms (Akt1-3) and is involved in cellular processes such as glucose metabolism, 
apoptosis, and cell proliferation.25,26 Aberrant Akt signaling is implicated in diabetes and 
in many cancers, making it an attractive drug and diagnostic target.27 This protein was thus 
chosen as a model target for PCC agent platform development. Several PCC agents were 
developed against the various domains of Akt – including the kinase domain, pleckstrin 
homology domain and the C-terminal hydrophobic motif – and the screening platform was 
greatly improved in the process. Chapter 2 describes the use of Akt-targeted PCC agents 
as antibody replacements in immunofluorescent imaging experiments. Akt is known to 
localize to the cell membrane upon cell stimulation and fluorescent PCC agents were able 
to visualize the membrane localization. A second set of PCC agents developed against the 
C-terminal domain of Akt demonstrated allosteric activation and inhibition of the protein’s 
enzymatic activity. Chapter 3 describes the functionalization of the allosteric Akt 
modulators with a cell penetrating peptide for cellular uptake in order to control Akt’s 
enzymatic activity in live cells.  
  
Also in Chapter 3 is the introduction of chemical degradation tags to PCC agents. An 
exciting new paradigm in drug discovery is the ability to induce protein degradation with 
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proteolysis targeting chimeric molecules, or PROTACs. A PROTAC is a 
heterobifunctional molecule that can form a ternary complex between a target protein and 
an E3 ubiquitin ligase by covalently linking existing ligands for each.28 When added to 
cells the PROTAC-induced association of the target protein with the E3 ligase results in 
ubiquitination and degradation of the target. The C-terminal Akt PCC agents were 
functionalized with a degradation tag and shown to induce degradation of Akt in cells.  
 
  Another exciting advance in PCC agent technology is the ability to target single amino 
acid point mutations on protein surfaces. Genetic mutation is often a key step in 
tumorigenesis, and selectively inhibiting the resultant mutant proteins is an attractive 
therapeutic strategy. The Akt1 gene was found to have a single point mutation (glutamic 
acid to lysine at position 17) in certain types of cancers.29 The E17K mutation of Akt is 
found in the pleckstrin homology domain and activates the protein by increasing its 
membrane association and thus activating the downstream signaling pathway. The PCC 
agent epitope targeting strategy was recently used to develop a capture agent that was 
selective for the oncogenic mutation and could inhibit Akt membrane localization. This 
new strategy opens the possibility of targeting other mutated oncoproteins. The 
oncoprotein K-Ras is another attractive target that is known to be a major driver in many 
human cancers. Finally, Chapter 4 of this thesis details efforts to target the oncoprotein K-
RasG12D with the PCC agent screening platform.  
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C h a p t e r  2  
PROTEIN CATALYZED CAPTURE AGENTS AS IMAGING PROBES 
TO VISUALIZE AKT SUBCELLULAR LOCALIZATION 
2.1 Summary of Contributions  
Parts of the contents of this chapter are adapted with permission from:  
(1)  Millward, S.W., Henning, R.K., Kwong, G.A., Pitram, S., Agnew, H.D., Deyle, K.M., 
Nag, A., Hein, J., Lee, S.S., Lim, J., et al. (2011). Iterative in Situ Click Chemistry 
Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1. J. Am. Chem. 
Soc. 133, 18280–18288. 
 This work was conducted in collaboration with Dr. Steven Millward. Steve led the study 
and carried out the majority of the experiments to identify and characterize the PCC agents 
reported here. I conceived of the imaging experiments, synthesized the necessary 
compounds, cultured the cells, and acquired the images. I also helped analyze the data and 
write the manuscript. The initial work is summarized and only the original data that I 
generated is included in this chapter. 
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2.2 Introduction  
 A critical bottleneck in the transition from a potential cancer biomarker to a clinical 
diagnostic tool is the availability of high-affinity, high-selectivity molecular entities to 
recognize and capture biomarkers from complex biological mixtures. Almost all current 
platforms employ antibodies as capture agents despite their high cost, poor stability,1,2 and 
the batch-to-batch variability that often characterizes biologicals. Many antibodies are poorly 
characterized, and reports have called into question the high specificity that is a perceived 
hallmark of antibodies.3,4 Emerging protein capture agent approaches, such as phage display 
peptides5 or nucleic acid aptamers, can potentially represent a powerful alternative to 
antibodies for certain diagnostic arrays.6,7 However, the challenge of finding a general and 
robust approach to produce protein capture agents that match the performance of monoclonal 
antibodies remains daunting. A high quality monoclonal antibody possesses a low-
nanomolar affinity and high target specificity. An ideal antibody replacement would be 
synthetically facile, be stable to a range of thermal and chemical conditions, and display high 
affinity and specificity for the target of interest.  
 
Iterative in situ click chemistry was used to develop a high-specificity, branched, triligand 
protein catalyzed capture (PCC) agent for the Akt kinase. Akt is a critical molecular router 
that mediates cellular signal transduction from the plasma membrane (cytokine receptors, 
GPCRs) to downstream effector molecules that control cell growth, apoptosis, and 
translation.8 Akt overexpression and/or hyperactivation has been observed in numerous 
cancer types.9 Such ubiquitous and aberrant Akt activity has made Akt a target for cancer 
  
14 
diagnostics and therapeutics.10 For developing a PCC agent against Akt, a novel screening 
strategy was developed. One can take advantage of the fact that an in situ click screen, in 
which an anchor ligand and protein target are screened against a large one-bead-one-
compound (OBOC) library, will selectively generate triazole-linked products on the hit 
beads. The presence of on-bead clicked product is thus taken to be the signature of a hit bead, 
leading to the concept of a product screen. Such a product screen was utilized to increase the 
affinity and selectivity of the final multiligand PCC agent.  
 
The Akt-binding PCC agent was developed by first identifying an anchor ligand. The initial 
anchor peptide was discovered by incubating the expressed kinase domain of Akt1 with a 
linear OBOC peptide library. The hit peptides were identified by probing the OBOC library 
for beads to which the protein was bound using Akt-specific antibodies. The consensus 
anchor sequence was identified as H2N-Az8-VFYRLGY-CONH2 (where Az8 is an unnatural 
amino acid with a side chain containing an eight carbon linker and a terminal azide) and the 
anchor showed a modest affinity of 25 µM. To increase the affinity of the anchor, a biligand 
branch was selected through a sequence of target and product screens. For these screens, the 
anchor peptide was modified with a C-terminal biotin for use in the product screen and 
incubated with an alkyne-containing, linear OBOC peptide library in the presence of the 
target protein. The most promising secondary ligand was identified as Pra-FWFLRG-
CONH2 and the resultant biligand showed an affinity of 338 nM. For triligand development, 
the in situ click screen was then iterated to identify a third ligand. The sequence of the tertiary 
ligand of the final branched PCC agent was RHERI and the Kd of the final triligand was 200 
nM. In order to test the utility of the PCC agent as a drop-in replacement for antibodies it 
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was employed in immunofluorescent imaging experiments. Fluorescent versions of the 
biligand and triligand were synthesized and used to stain cells in order to monitor the 
subcellular localization of Akt.  
 
2.3 Results and Discussion 
To explore the biological applications of PCC agents, we asked if these compounds can be 
used as labeling agents in immunofluorescent imaging experiments. To address this question, 
fluorescent Akt biligand and triligand (Figures 2.1 and 2.3) were synthesized and used to 
stain fixed and permeabilized OVCAR3 cells and compared with a fluorescein-labeled anti-
Akt monoclonal antibody. Previous studies have shown that Akt2 is overexpressed in the 
OVCAR3 ovarian cancer cell line, and so we utilized this cell line as an experimental 
platform for the immunocytochemical experiments (ICC).11 When cellular receptor tyrosine 
kinases are activated, Akt is known to localize to the inner leaflet of the plasma membrane 
through biding of its pleckstrin homology domain (PHD) to phosphatidylinositol (3,4,5)-
triphosphate (PIP3).
12 Thus, we sought to visualize Akt membrane localization by imaging 
OVCAR3 cells stimulated with EGF and/or Insulin. When cells were stained with the 
fluorescent biligand the effect was visible, but it was not as profound (Figure 2.2) — this 
may be due to some of the off-target binding in the biligand. We also later found that the best 
images were obtained when cells were stimulated with both EGF and insulin, while the 
biligand images were acquired after stimulation with EGF alone. When imaging with the 
fluorescent triligand (Figure 2.3), which has much improved specificity over the biligand, 
AKT membrane localization was much more apparent (Figure 2.4). These results 
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demonstrate the ability of PCCs to selectively bind their targets in complex cellular 
environments. 
 
2.4 Conclusion   
The ultimate test of a protein capture agent is whether or not it can be used to detect its 
cognate protein from a biologically relevant sample. Visualization of Akt membrane 
localization in the complex cellular milieu corroborates the in vitro biochemical data and 
confirms that the PCC agent screening platform is a viable approach to develop protein 
binders with high affinity and selectivity. In addition, fluorescence imaging has become a 
standard benchmark for PCC agent performance in subsequent studies.13–15 
 
2.5 Materials and Methods 
Peptide Synthesis 
 In general, peptides were synthesized using standard SPPS protocols either manually or 
on a Titan 357 automated peptide synthesizer (Aapptec). Briefly, FMOC resins were 
swelled in NMP and deprotected with 20% piperidine. Per coupling reaction, 4 equivalents 
of Fmoc-amino acid, 3.9 equivalents of HATU, and 12 equivalents of DIEA were added 
(equivalents relative to loading capacity of the resin). Couplings proceeded for 30-45 
minutes. Azido amino acids were added at 2 equivalents relative to the resin loading 
capacity. The N-termini were acetylated with 20 equivalents of acetic anhydride and 10 
equivalents of DIEA. In cases where use of Azido- amino acid Az8 produced a mixture of 
two diastereomers, the diastereomers were purified as a single product unless otherwise 
noted. 
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Synthesis of Fluorescein-biligand 
The anchor peptide VFYRLGY-CONH2 was synthesized on Rink Amide resin (Anaspec). 
Following addition of Az8, the resin was washed with NMP and set aside (Fmoc-Az8-
VFYRLGY-CONH2). In parallel the secondary ligand (Pra-FWFLRG-CONH2) was 
synthesized on Sieber amide resin. After Fmoc deprotection the fluorescein derivative 6-
[Fluorescein-5(6)-carboxamido]hexanoic acid (Sigma) was then conjugated to the amino 
terminus of the secondary peptide using 1.2 equivalents of fluorescein, 1.1 equivalents of 
HATU and 3 equivalents of DIEA and incubated at room temperature for 30 minutes. The 
peptide was cleaved by adding 4.5 mL 2% TFA in CH2Cl2 and incubating for 5 minutes. 
The TFA was quenched by filtration into 225 μL DIEA. The cleavage was repeated five 
times, the filtrates were combined, and the solvent removed by rotary evaporation. The 
protected fluorescent secondary peptide was then purified by C18 RP-HPLC with a 
dH2O:CH3CN (0.1% TFA) gradient. The product was confirmed by MALDI-TOF MS. 
The secondary peptide was coupled to the anchor peptide via copper catalyzed azide-
alkyne cycloaddition by addition of 1 equivalent of anchor peptide with 2 equivalents of 
fluorescent secondary peptide, 4 equivalents of CuI, and 6 equivalents of Ascorbic Acid. 
The reaction proceeded for 18 hours at room temperature followed by washing in NMP 
and copper chelation solution. The N-terminal Fmoc group was removed in 20% 
piperidine. 8 equivalents of 5-hexynoic acid (Sigma), 7 equivalents of HATU, and 24 
equivalents of DIEA were added in NMP and the reaction was allowed to proceed at room 
temperature for 2 hr. After washing with NMP, the 5HA-Fluorescent-Biligand was cleaved 
from the resin in 95:5:5 TFA:dH2O:TES and precipitated in diethyl ether. The product was 
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purified by RP-HPLC as a mixture of diastereomers and analyzed by MALDI-TOF mass 
spectrometry (Expected [M+H]+= 2612.00, Observed [M+H]+ = 2612.78).  
 
Synthesis of Fluorescein-triligand 
 For the synthesis of the fluorescent triligand, the biligand was synthesized as described 
above without the addition of the fluorescent dye. The tertiary peptide Az8-RHERI-
CONH2 was synthesized on Rink Amide resin as described. Following deprotection of the 
N-terminal Fmoc group, the resin-bound tertiary peptide was reacted with 1.2 equivalents 
of 6-[Fluorescein-5(6)-carboxamido]hexanoic acid (Sigma), 1.1 equivalents of HATU, and 
3 equivalents of DIEA at room temperature for 30 minutes. Following cleavage from resin, 
C18 RP-HPLC purification and MALDI-TOF verification of the product, the fluorescein-
labeled tertiary peptide was coupled to 5HA-Biligand-Bio via copper catalyzed azide-
alkyne cycloaddition by addition of 1 equivalent of fluorescein-labeled tertiary peptide to 
1.15 equivalents of 5HA-Biligand-Bio, and 3 equivalents of TBTA in the presence of 10 
mM CuI and 30 mM L-ascorbic acid in 4:1 NMP:water. The reaction proceeded for 24 
hours at room temperature. The fluorescent triligand was purified by RP-HPLC and 
analyzed by MALDI-TOF MS: Expected [M+H]+ = 3841.0, Observed [M+H]+ = 3840.8. 
 
Immunofluorescence Microscopy 
OVCAR3 cells were grown on poly-lysine coated cover slips, then serum starved for 1 hr. 
The cells were then treated with either 400 ng/mL EGF (Sigma) or 20 μg/mL insulin 
(Sigma) or untreated for 10 minutes. Cells were then fixed with 10% formaldehyde for 10 
min at 37 °C, washed with PBS, permeabilized by incubating with 0.1% Triton X-100 for 
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5 min at room temperature, and blocked with 5% goat serum. Permeabilized cells were 
stained with either a fluorescein-conjugated Pan Akt antibody (R&D Systems IC2055F, 10 
μg/mL) overnight, 1 μM fluorescein conjugated biligand for 1 hour, or 100 nM fluorescein-
triligand for 1 hr. Images were acquired using a Zeiss Pascal 5 Laser Scanning Microscope 
(Caltech Biological Imaging Center). 
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2.6 Figures 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1 – Chemical structure of fluorescent Akt biligand 
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Figure 2.2 – Imaging Akt membrane localization with fluorescent 
biligand. OVCAR3 cells stimulated with or without EGF and stained with a 
fluorescent anti-AKT antibody (Ab) or the AKT biligand (BL).  
  
22 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.3 – Structure of fluorescent Akt triligand 
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Figure 2.4 – Imaging Akt with fluorescent triligand PCC agent. 
Immunofluorescent images of Akt in fixed OVCAR3 cells stained with either a 
fluorescein-conjugated anti-Akt antibody (Ab) or a fluorescein-conjugated triligand 
(TL). Each imaging agent distinguishes cytoplasmic or membrane-bound Akt in 
unstimulated or EGF+insulin-treated cells, respectively. Contrast is enhanced 
equally in all images, but the fluorescence images of the triligand stained cells were 
achieved at a 3-fold lower excitation laser intensity relative to the (much dimmer) 
antibody-stained cells. Scale bar = 100 μm. 
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C h a p t e r  3  
ACTIVATION, INHBITION, AND DEGRADATOIN OF AKT USING 
PROTEIN CATALYZED CAPTURE AGENTS 
3.1 Summary of Contributions  
Adapted with permission from:  
(1) Henning, R.K., Varghese, J.O., Das, S., Nag, A., Tang, G., Tang, K., Sutherland, A.M., 
and Heath, J.R. (2016). Degradation of Akt using protein-catalyzed capture agents. J. 
Pept. Sci. 22, 196–200. 
 
This work was performed in close collaboration between Dr. Joseph Varghese and myself as 
indicated in our co-first authorship on resultant publication from our efforts. In the early 
stages of the project Joey optimized several reactions that were necessary for synthesizing 
the PCC agents used in the study, such as the TAT cleavage reaction. Together we worked 
closely to synthesize, purify, and characterize the compounds reported and we also 
collaborated while conducting several of the assays. My unique contribution was the 
incorporation of the degradation tag for PROTAC development. 
 
 
 
 
 
  
27 
3.2 Introduction 
Protein-catalyzed capture (PCC) agents are a class of ligands that are built using in situ 
click chemistry1 to allow a protein of interest to select its own high-affinity binders.2 These 
synthetic peptides have some similarities to monoclonal antibodies, but are a fraction of 
the size and can exhibit a high level of stability.3 A recent advance of this technology 
permits the targeted development of a PCC against a specific epitope of a given protein.4,5 
Unlike the case for small molecule ligands, the generalized PCC epitope targeting strategy 
does not rely on the presence of a hydrophobic binding pocket. This opens up several non-
traditional approaches towards altering enzymatic activity, including the targeting of sites 
that can allosterically influence that activity6 or by disrupting protein-activator 
associations.7 A second possibility is simply to use the synthetic flexibility of the PCC 
agent as a selective targeting moiety for labeling the target with a molecular signal, such 
as a degradation signal, as is used for the case of proteolysis targeting chimeric molecules 
(PROTACs). Here, we explore the use of a pair of epitope-targeted PCC agents developed 
against an allosteric site of Akt2 for in-cell allosteric activation, inhibition, and degradation 
of Akt. 
 
We previously reported the development of a pair of PCC agents targeting the C-terminal 
hydrophobic motif of Akt2 that includes the Ser474 residue.5 Phosphorylation of Akt at 
Ser474 leads to allosteric activation of Akt and increases the kinase activity tenfold.8 We 
therefore hypothesized that targeting the Ser474 site could lead to compounds that 
influence Akt kinase activity. We increased the interaction footprint of the initial epitope-
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targeted 5-mer peptide ligand with Akt2 by expanding it into two distinct triligands 
through in situ click chemistry screens. The two PCC agent triligands, tri_a and tri_i, 
developed from the same epitope-targeted the anchor peptide, were shown to activate and 
inhibit Akt enzymatic activity respectively, in in vitro kinase assays.5 
 
Although specific peptides (typically macrocycles) have been designed for cell entry,9 the 
tri_a and tri_i PCC agents are branched structures consisting of linear branches, and so do 
not naturally enter into live cells. A common approach for cellular delivery of peptides is 
to append a cell penetrating peptide (CPP),10 and that is the route we choose here. CPP-
labeled tri_a was found to penetrate into live cells. The influence of the CPP-labeled 
compounds on in-cell kinase activity and on cellular proliferation were then explored in 
two cancer cell lines. We next modified the two triligands to present a HIF-1α degradation 
signal and explored the capacity of these compounds to promote in-cell Akt degradation. 
 
3.3 Results and Discussion  
We conjugated the PCC agents to the HIV TAT peptide, which is a CPP that efficiently 
penetrates cell membranes via endocytosis, and allows CPP-bound molecules to enter 
cells.11 Figure 3.1A shows the structure of TAT-conjugated tri_a, where the TAT sequence 
is separated from the capture agent by two PEG spacers placed on either side of a protected-
lysine residue. This permits further functionalization as desired during the solid phase 
peptide synthesis via the lysine ε-amino group (adding a dye, signaling peptide, etc.). To 
validate cellular uptake, we treated U87 cells with fluorescein-labeled tri_a (CPP-tri_a-
FL, Figure 3.1B and Figure 3.7) and acquired simultaneous fluorescence and transmission 
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images. U87 cells are particularly useful for imaging because they grow in a uniform 
monolayer.12 We found that the CPP-tri_a-FL is able to efficiently penetrate the cell 
membrane and enter the cells. No fluorescence signals were detected outside the cells, and 
the uniform distribution of the fluorescence through the cell cytoplasm suggests that the 
PCCs were released into the cells (rather than completely trapped within endosomes).  
 
We next performed functional assays to confirm that the in vitro effects translate into live 
cells. The enzymatic activity of Akt can be monitored by measuring the phosphorylated 
level of its direct substrate, glycogen synthase kinase 3 beta (GSK-3β).13 SKOV3 ovarian 
cancer cells were dosed with TAT-coupled tri_a (CPP-tri_a, Figures 3.1A and Figure 3.6) 
for various times. Following cell lysis, the relative levels of various proteins were measured 
via western blotting (Figure 3.2A). Both untreated cells and EGF-stimulated cells were 
used as controls. The level of phospho(p)-GSK-3β was seen to increase after 1 h of 
treatment, decrease over the next few hours, and finally increase once more – perhaps 
alluding to a feedback mechanism in the cell. The initial increase in the p-GSK-3β level 
indicates that the capture agent is binding Akt and stimulating its enzymatic activity in 
cells. The p-Akt level initially increases and then steadily decreases over time. Notably, 
EGF-stimulated cells display a large increase in p-Akt, but the corresponding level of p-
GSK-3β in EGF-stimulated cells is still lower than the initial levels in cells treated with 
CPP-tri_a. 
 
We next performed an XTT cell proliferation assay to determine if Akt activation by CPP-
tri_a stimulates cell proliferation.14 Dehydrogenase enzymes in live cells reduce XTT 
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tetrazolium salt to a vividly colored formazan dye that can be used to quantify the 
number of viable cells.15,16 We found that CPP-tri_a affected both OVCAR3 and SKOV3 
cell lines (Figure 3.2B). Interestingly, for both cell lines, a sharp increase in proliferation 
after 24 h is followed by a steady decrease over a few days – once more suggesting a 
possible feedback mechanism. Eventually, after several days of treatment, cellular 
proliferation falls back to baseline levels for SKVO3 cells while OVCAR3 cells are 
inhibited relative to the untreated control. An initial increase in cell number after treatment 
with CPP-tri_a is consistent with previous studies showing that Akt activation promotes 
cell cycle progression during the G1 and G2 phases of the cell cycle.17,18 Additionally, 
activated Akt is known to inhibit the pro-apoptotic bad protein,19,20 as well as the FoxO 
and Myc family of proteins.21,22 Such enhanced cell proliferation can be used in beneficial 
ways. Many pathological disorders are associated with aberrant cell death signaling, 
including various neurodegenerative diseases.23 Akt activation was recently shown to 
prevent neuronal cell death.24 Thus, an Akt activator might prove useful as a tool to probe 
the Akt signaling pathway and to help develop potential therapeutics for disease-associated 
apoptosis abnormalities. In any case, these results further corroborate the in vitro data that 
tri_a directly activates Akt. 
 
Similarly, the TAT-modified tri_i (CPP-tri_i, Figure 3.3) inhibits phosphorylation of GSK-
3β and reduces cancer cell viability (Figure 3.4). SKOV3 cells were treated with 50 µM 
CPP-tri_i for various times, lysed simultaneously, and analyzed by western blot (Figure 
3.4A). Cells treated with tri_i show less phospho-GSK-3β than untreated or EGF 
stimulated cells over the entire 24 hour time course. Similar to CPP-tri_a, CPP-tri_i 
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inhibition of Akt appears to be independent of Akt phosphorylation at Ser473. 
Additionally, CPP-tri_i also inhibits cell proliferation. SKOV3 and OVCAR3 cells each 
show an initial drop in cell viability upon treatment with CPP-tri_i, with values remaining 
consistently lower than untreated cells for 5 days (Figure 3.4B). The results from the XTT 
assays are consistent with the expected phenotypic outcome of Akt inhibition. 
 
Proteolysis targeting chimeric molecules represent an example of using cellular signals to 
control levels of specific proteins.25,26 In particular, PROTACs utilize the quality control 
machinery of the cell by artificially labeling proteins for proteasomal degradation. We 
sought to create Akt PROTACs by encoding a peptide ligand for the E3 ubiquitin ligase 
von Hippel Lindau protein directly into the CPP-labeled PCC agents.27 The peptide 
represents the von Hippel Lindau binding site from hypoxia-inducible factor (HIF-1α) 
protein. 
 
When OVCAR3 cells were treated with CPP-tri_a-PR over a variable time period up to 
24 h Akt levels diminished. After 30 min of treatment, a relative decrease in Akt level was 
measurable, with a continuing decrease that reached a nadir after 4 h (Figure 3.5A). 
Similarly, CPP-tri_i was also modified into a PROTAC (CPP-tri_i-PR, Figure 3.9) and 
effectively removed Akt from cells, with a slightly slower time constant (Figure 3.5B). We 
also observed a dose-dependent decrease in Akt upon treatment with the CPP-tri_a-PR 
and determined an EC50 degradation constant of 128 ± 19 μM (Figure 3.5C). 
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3.4 Conclusion 
Previous PROTACs have been developed by adding a degradation signal to a modified 
protein ligand28 or previously discovered inhibitors.29,30 Here, we report that epitope-
targeted PCC agents can be modified into PROTACs to direct synthetic degradation to 
specific proteins in cells. We also show an Akt activator and inhibitor can both serve as 
PROTACs (Figure 3.5), indicating that ubiquitination and degradation of this protein can 
be induced regardless of the activation state of the protein. Targeting proteins for enzymatic 
destruction is an attractive alternative to developing traditional small molecule inhibitors, 
especially for proteins (such as Akt) that are difficult to inhibit with traditional methods.31 
 
The principle concept reported here is the use of an epitope-targeted PCC as simply a 
vehicle for directing PROTAC-initiated degradation to a specific target. A limitation of 
this approach, as reported, is that the PCCs are not intrinsically cell penetrant, and so were 
modified with a CPP for the in-cell assays. We have recently reported on epitope-targeted 
macrocyclic PCC agents,4 and such peptide architectures have been modified for both cell 
permeability9,32,33 and other desired pharmacokinetic properties.34 Other promising 
proteolysis tags include members of the IMiD family, such as thalidomide, which is a drug 
with a rich history.35 In 2010, it was discovered that thalidomide targets the E3 ubiquitin 
ligase member cereblon.36 Related examples of cereblon-targeted degradation include the 
use of pomalidomide37 and phthalimide38 for PROTAC development. 
 
3.5 Materials and Methods  
Solid phase peptide synthesis general protocol:  
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Peptides were synthesized on Rink Amide MBHA, Biotin Novatag, and Sieber Amide 
resin either manually, on a Liberty1 Microwave Peptide Synthesizer (CEM), or on a Titan 
357 Automatic Peptide Synthesizer (AAPPTec). Peptide coupling reactions were done in 
NMP with 2 equivalents of amino acid, 2 equivalents of HATU and 6 equivalents of N,N-
Diisopropylethylamine (Sigma). For removal of Nα-Fmoc protecting groups, a solution of 
20% piperidine in NMP was used.  
 
Acylation 
 The resin was treated twice for ten minutes with a solution of anhydrous acetic anhydride 
and DIEA in NMP (acetic anhydride: DIEA: Peptide; 40:20:1) at room temperature. Excess 
reagent was removed by washing five times successively with NMP.  
 
Cleavage of side chain protected peptides 
 The peptides were synthesized on Sieber Amide resin and cleaved by washing three times 
for one minute with 1% TFA/DCM, and finally washed with DCM. The acidic peptide 
solution was neutralized using 2 equivalents of DIEA followed by removal of the solvent 
by rotary evaporation. The remaining semisolid was dissolved in filtered DMSO, HPLC 
grade acetonitrile, and double distilled water, and purified via HPLC.  
 
Cleavage of side chain deprotected Biotin Linker peptide 
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 The peptides were synthesized on Biotin Novatag resin. The dried resin was then treated 
with a TFA cleavage solution of 95% TFA, 2.5% H2O, and 2.5% triethylsilane for two 
hours at room temperature. The cleavage solution was filtered to remove the resin and 
added dropwise to an ice-cooled solution of diethyl ether.  
 
Cleavage of TAT-containing peptides 
 TAT-containing peptides were synthesized on Rink Amide MBHA resin. The dried resin 
was then incubated with a TFA cleavage solution of 80% TFA, 10% thioanisole, 5% H2O, 
5% triethylsilane for 3 hours at room temperature. The cleavage solution was filtered to 
remove the resin and added dropwise to a cooled solution of diethyl ether. 
 
HPLC purification of peptides 
 All peptides were purified using a preparative or semi-preparative scale HPLC with a C18 
reverse phase column. A gradient of double distilled water and HPLC grade acetonitrile 
and 0.1% TFA was used for all purifications. 
 
Protocol for on-bead copper (Cu) catalyzed azide alkyne cycloaddition (CuAAC) click 
reaction 
 On-bead Cu catalyzed click reactions were performed with the azide on bead and the 
alkyne in solution. The resin was treated with 2 equivalents of the relevant alkyne, 1.5 
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equivalents of CuI (Sigma), and 2.5 equivalents of ascorbic acid (Sigma), in a solution 
of 20% piperidine in DMF. The reaction was performed overnight at room temperature. 
Excess copper was removed from the resin by washing with a Cu chelating solution (5% 
(w/v) sodium diethyl dithiocarbamate, 5% (v/v) DIEA in DMF).  
 
Removal of Dde protecting group 
 For removal of Dde protecting groups, resin-bound peptide was washed with a solution of 
2% hydrazine in DMF three times for ten minutes. 
 
Mass spectrometry analysis 
 All intermediate and final peptides were analyzed via MALDI-TOF-MS using a Voyager 
DE-PRO MALDI TOF-MS system (Applied Biosystems). Peptides were dissolved in 
50:50 water/acetonitrile with 0.1% trifluoroacetic acid at a final concentration of 10 
pmol/µL. 1 µL of the peptide sample was then added to 10 µL of a saturated solution of 
MALDI matrix, either α-cyano-4-hydroxycinnamic acid or Sinapinic Acid, in 50:50 
water/acetonitrile with 0.1% trifluoroacetic acid and analyzed via MALDI-TOF MS.  
 
Synthesis of CPP-tri_a 
 For the synthesis of the N-terminal triligand the HIV-TAT sequence H2N-
GRKKRRQRRRPPQQ-CONH2 was synthesized on rink amide MBHA resin using 
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standard SPPS conditions. Fmoc-PEG5-COOH was then coupled to the N-terminus of 
the resin-bound TAT peptide with 1.5 equivalents of PEG5, 1.5 equivalents of HATU and 
4.5 equivalents of DIEA. Following the PEG5 coupling and subsequent Fmoc deprotection 
Fmoc-Lysine(Dde)-OH was then coupled using standard conditions. After the Lys(Dde) 
coupling and deprotection a second PEG5 group was added. The N-terminal triligand was 
then synthesized on the resin bound PEG5-Lys(Dde)-PEG5-TAT peptide as previously 
reported.5 The Dde group was then removed and the peptide was either cleaved/deprotected 
and purified for assays or further modified at the epsilon amino group of the lysine side 
chain at the linker region. The TAT-conjugated triligands were cleaved from the resin in 
80:10:5:5 TFA:thioanisole:TES:H2O for 2.5 hours. Expected [M+H]+ = 6047.1, Observed 
[M+H]+ = 6049.9. The molecular structure of CPP-tri_a is shown in Figure 3.6  
 
Synthesis of fluorescently labeled CPP-tri_a 
 To resin-bound N-terminal triligand described above, 5-Carboxyfluorescein was coupled 
to the epsilon amino group of the lysine side chain at the linker region. The coupling 
reaction was performed with 1:1.5:1.5:4.5 ratios of peptide:5-
Carboxyfluorescein:HATU:DIEA. The peptide was then cleaved and purified with the 
same conditions as the unlabeled N-terminal triligand. MALDI-TOF MS: Expected 
[M+H]+ = 6405.4, Observed [M+H]+ = 6408.7. The molecular structure of CPP-tri_a-FL 
is shown in Figure 3.7. 
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Synthesis of CPP-tri_a-PR with HIF-1α degradation signal 
To resin-bound N-terminal triligand previously described, 6-aminohexanoic acid(Ahx) 
followed by the HIF-1a degradation peptide ALAPYIP were coupled to the epsilon amino 
group of the lysine side chain at the linker region using standard SPPS conditions. The 
peptide was then cleaved and purified with the same conditions as the unlabeled N-terminal 
triligand.  MALDI-TOF MS: Expected [M+H]+ = 6886.1, Observed [M+H]+ = 6885. The 
molecular structure of CPP-tri_a-PR is shown in Figure 3.8.   
 
 
Synthesis of CPP-tri_i inhibiting triligand 
Unlabeled C-terminal triligand was synthesized as previously reported.5 Fmoc-PEG2-
COOH was then coupled to the N-terminus of the resin-bound peptide with molar ratios of 
1:1.5:1.5:4.5 peptide:PEG2:HATU:DIEA. Ahx followed by cysteine were then coupled 
using standard conditions and 5-carboxyfluorescein was coupled as before resulting in 
compound 1. Fluorescent C-terminal triligand was then cleaved with 95:2.5:2.5 
TFA:H2O:TES and HPLC purified. The observed MALDI-TOF MS [M+H]+ = 4001.6, 
which is +4 amu from expected [M+H]+ = 3997.6, most likely due to oxidation of 
tryptophan to kynurenine39 – tryptophan oxidation is a known artifact in MS of petides.40  
Dibenzocyclooctyne-maleimide (Sigma) was then coupled to the cysteine thiol group as 
reported41 to yield cyclooctyne C-terminal triligand 2 (Figure 3.10). The crude mixture was 
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then HPLC purified and a single peak at 495 nm (Fluorescein λmax) was collected 
corresponding to compound 2.  
 
Azide-containing TAT peptide 3 was synthesized using standard conditions and Fmoc-
PEG2-COOH was coupled as before followed by addition of 5-azidopentanoic acid using 
standard coupling conditions. Resin-bound 3 was then cleaved and purified with conditions 
mentioned above. Peptides 2 and 3 were then clicked together as reported41 resulting in C-
terminal triligand 4 (Figure 3.11 ). The crude mixture was then injected onto a semiprep 
C18 reverse phase HPLC column and new peak appeared that was distinct from the HPLC 
traces of compounds 2 and 3 alone, corresponding to peptide 4. Peptide 2 elutes from the 
analytical HPLC beginning around 18 minutes and TAT peptide 3 begins eluting around 8 
minutes. After the strain-promoted click reaction peptide 4 elutes after approximately 11 
minutes.  MALDI-TOF MS: Expected [M+H]+ = 6582.6, Observed [M+H]+ = 6599.1. The 
+16 difference is likely due to oxidation of the peptide in the MALDI-TOF.  
 
Synthesis of CPP-tri_i-PR with HIF-1α degradation signal 
Resin-bound HIV-TAT peptide H2N-PEG5-Lys(Dde)-PEG5-GRKKRRQRRRPPQQ-
CONH2 was synthesized as described above. The C-terminal triligand was then synthesized 
onto the TAT peptide as before. The ε-amino group of the Lys(Dde) in the linker region 
was then deprotected and the degradation sequence Ahx-ALAPYIP was added by SPPS as 
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with the N-terminal triligand. [M+H]+ = 6641.81, Observed [M+H]+ = 6641.89. The 
molecular structure of CPP-tri_i-PR is shown in Figure 3.9.   
 
Cell Culture 
All cell lines were purchased from American Type Culture collection Q4 (Manassas, VA, 
USA). U87 (ATCC number HTB14), OVCAR3 (ATCC number HTB161), and SKOV3 
(ATCC number HTB77) cells were cultured under conditions specified by the provider. 
 
Fluorescence Microscopy 
Cells were seeded onto chambered cover glass slides (Sigma-Aldrich, St. Louis, MO, USA) 
and allowed to attach overnight. The following day, cells were serum starved and treated 
with fluorescent capture agent. Live cells were then imaged using a Zeiss (Oberkochen, 
Germany) LSM5 Exciter microscope in the Caltech Biological Imaging Center. 
 
Immunoblotting 
Western blots were performed according to standard protocols. Briefly, cells were lysed 
with cell lysis buffer (Cell Signaling Technology) containing protease and phosphatase 
inhibitors (Cell Signaling Technology). Cell lysates were quantified with a Bradford 
protein assay (Thermo Scientific, Waltham, MA, USA) and prepared for gel 
electrophoresis in Laemmli sample buffer and reducing agent. Twenty micrograms of cell 
lysate were added to precast polyacrylamide gels (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA), and proteins were separated by electrophoresis followed by transfer to PVDF 
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membrane. Membranes were then blocked and probed with primary antibodies followed 
by horseradish peroxidase-conjugated secondary antibodies. The bands were visualized via 
a chemiluminescent substrate (Thermo Scientific). The following antibodies were used 
according to manufacturer protocol: p-GSK3β (Cell Signaling, 9323), GSK3β (Cell 
Signaling, 12456), AKT (Cell Signaling, 4691), p-AKT (S473) (Cell Signaling, 4060), 
Actin (Cell Signaling, 8456), and HRP-linked Anti-rabbit IgG (Cell Signaling, 7074). 
 
Cell Proliferation Assay 
Cell viability kit II (XTT) assay was purchased from Cell Signaling Technology (#9095) 
and used according to manufacturer protocol. Briefly, 1x104 cells per well were seeded in 
a 96-well plate. The following day, cells were serum starved and treated with PCC agent. 
Following treatment, XTT was added to the media, and after 1 h, the absorbance at 450nm 
was measured. 
 
In-cell ELISA Assay 
In-cell ELISA kits were purchased from Thermo Scientific (#62215) and used according 
to manufacturer protocol. Briefly, 1 × 104 cells were seeded in 384-well plates and allowed 
to attach overnight. The following day, cells were serum starved and treated with capture 
agent. Following capture agent treatment, cells were fixed, permeabilized, blocked, and 
then stained with primary and HRP-conjugated secondary antibody and developed with 
colorimetric peroxidase substrate. The absorbance was measured at 450 nm to quantify the 
protein. Cells were then incubated with Janus Green whole-cell stain, and the absorbance 
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was measured at 615 nm to quantify relative number of cells per well. The Akt signal 
was then normalized to the relative cell number for each well to determine the Akt/cell. 
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3.6 Figures 
  
Figure 3.1 – Exploiting the modularity of Akt-activating PCC agent tri_a. (A) Structure of Akt-
activating N-terminal triligand, tri_a. The lysine residue between the PEG spacers can be further 
functionalized with fluorescein or the degradation-inducing Hif-1α peptide. Complete structures are 
shown in the subsequent figures. R = H is referred to as CPP-tri_a, R = fluorescein is CPP-tri_a-
FL, and R = ALAPYIP (Hif-1α degradation peptide) is CPP-tri_a-PR. (B) Live-cell confocal 
images of the fluorescein-labeled capture agent CPP-tri_a-FL delivered into U87 cells. 
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Figure 3.2 - tri_a activates Akt in cells. (A)Western blots of SKOV3 cells treated with 
50 μM CPP-tri_a. Densitometry was performed on the p-GSK-3β blot, and the relative 
intensities were plotted on the bar graph below the blotting assays. (B) XTT cell 
proliferation assay results from OVCAR3 and SKOV3 cells treated with 50 μM CPP-
tri_a for times varying from 1 to 5 days. A student’s t-test was used to determine 
significant differences where * = p-value ≤ 0.05 and *** = p-value ≤ 0.01. 
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Figure 3.3 - Structure of Akt-inhibiting CPP-tri_i 
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A B 
Figure 3.4 – CPP-tri_i inhibits Akt in cells. (A) Western blots of SKOV3 cells treated with 50 μM CPP-
tri_i. Cells were treated for various times and compared with 100 ng/mL EGF stimulation and an untreated 
control. Densitometry was performed on the p-GSK-3β blot and the relative intensities were plotted on the 
graph below. (B) XTT results from OVCAR and SKOV3 cells treated with 50 μM CPP-tri_i for 1-5 days. 
Each point shows a decrease in relative proliferation compared to the control. A student’s t-test was used to 
determine significant differences where * = p-value ≤ 0.05 and *** = p-value ≤ 0.01. 
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Figure 3.5 – PCC agent-induced degradation of Akt (A) In-cell ELISA measurement of Akt in 
OVCAR3 cells treated with CPP-tri_a-PR for various times. (B) In-cell ELISA measurement of 
Akt in OVCAR3 cells after treatment with 100 μM tri_i-PR for various times. (C)In-cell ELISA 
measurement of Akt after 4 hour treatment at variable CPP-tri_a-PR doses. Results show dose-
dependent degradation of Akt with an EC
50
 value of 128±19 µM 
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Figure 3.6 - Structure of CPP-tri_a 
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Figure 3.7 - Structure of CPP-tri_a-FL 
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Figure 3.8 - Structure of the CPP-tri_a-PR 
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Figure 3.9 - Structure of CPP-tri_i-PR 
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Figure 3.10 – Reaction scheme for synthesizing cyclooctyne-containing tri_i. The C-terminal 
triligand was synthesized with a cyclooctyne via thiol-maleimide conjugation for copper-free click 
chemistry.  
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Figure 3.11 – Reaction scheme for synthesizing CPP-tri_i. The C-terminal triligand, CPP-tri_i was 
synthesized with via copper-free click chemistry by reacting the cyclooctyne-containing C-terminal 
triligand with azide-containing TAT peptide.  
4 
2                     +                    3 
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C h a p t e r  4  
DISCOVERY OF THE FIRST SELECTIVE LIGANDS AGAINST 
THE MUTANT ONCOPROTEIN K-RASG12D  
 
4.1 Summary of Contributions  
I have worked independently on this project for the majority of its existence. I identified the 
target and the degradation strategy and have conducted the majority of the experiments 
myself. However, I did greatly benefit from several technical advances to the screening 
platform that were made by my colleagues such as the epitope targeting strategy and the 
macrocyclic peptide libraries. I also received help from several amazing summer students 
over the years. This work has not yet been published but a patent application is currently 
pending.  
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4.2 Introduction 
The KRAS oncogene is a member of the Ras family of GTPases that are involved in 
numerous cellular signaling processes.1 The Ras protein can act as a molecular switch by 
adopting two distinct conformations, depending on the nucleotide that is bound to the 
protein. When bound to GTP Ras is in the active state and sends downstream signals that 
result in cell division. Ras is inactivated upon GTP hydrolysis to GDP and cells can then 
enter a resting state.2 Activating Ras mutations are present in up to 30% of all tumors, 
including as many as 90% of pancreatic cancers.3 K-Ras is the Ras family member that 
most often associated with tumorigenesis. Ras mutations tend to abrogate the enzymatic 
activity and render the protein constitutively active due to the persistent GTP-bound state 
- active Ras will then result in increased cell proliferation due to upregulation of the MAPK 
and PI3K pathways, respectively.4 Due to the clinical significance of this protein, many 
attempts have been made to develop Ras inhibitors but no targeted therapy has been 
developed thus far. This is largely due to the difficulty in outcompeting GTP for the K-Ras 
binding pocket in cells, and the lack of known allosteric regulatory sites.5  
 
A recent study presented the first compounds that specifically target a mutant form of K-
Ras.6 Non-small cell lung cancer often presents a K-RasG12C mutation that is associated 
with poor prognosis.7 The nucleophilicity of the cysteine thiol group can be targeted with 
electrophilic compounds and screening K-RasG12C against such a chemical library yielded 
promising hits that could inhibit the mutant protein – efforts are now underway to optimize 
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these compounds towards potential clinical candidates.8 However, this strategy is not 
applicable to targeting other more common Ras mutations. 
 
The most common K-Ras mutation is glycine 12 to aspartic acid (G12D) – this mutation 
accounts for nearly half of all K-Ras oncoproteins.9 We recently used an in situ click 
chemistry screen to identify PCC agents that are the first known compounds that bind K-
Ras with preference for the oncogenic G12D mutation. Our compounds are capable of 
binding to the surface of K-Ras, thus circumventing difficulties encountered in previous 
research where a binding pocket was needed.  
 
4.3 Results and discussion 
 
Epitope targeting screen. To develop these new compounds we used the epitope-targeting 
PCC agent platform to target the specific region of interest.10 First, the non-cancerous wild-
type K-Ras epitope encompassing the glycine 12 residue was synthesized (Figure 4.1A). 
The leucine residue near glycine 12 was replaced with propargylglycine in order to provide 
a click handle where members of an azide library could then bind. This azide library was a 
macrocyclic one-bead-one-compound (OBOC) peptide library with 1.4x106 unique 
members (Figure 4.2).11 Approximately 200 hits clicked to the wild-type K-Ras fragment, 
and were removed from the screen in order to avoid selecting hits that bind to the wild-
type protein (Figure 4.3). The remaining beads were then incubated with another 
propargylglycine-functionalized fragment – this time containing the oncogenic G12D 
mutation (Figure 4.1B) – and seven hit beads were identified. The seven hits yielded nine 
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potential compounds due to ambiguity in some of the sequencing results (Table 4.1). The 
nine sequences were then synthesized and tested for binding to the full-length K-RasG12D 
protein by ELISA assays (Figure 4.4, Appendix A). The best binder was also tested for 
selectivity to wild type or G12D K-Ras and showed a preference for K-RasG12D. Hit seven 
demonstrated the best performance in the single point ELISA assays and the variable region 
was identified as LRGDR. Hit 7b, which was subsequently renamed 7b1 after a second 
series of compounds was generated, has an affinity for K-RasG12D of 33 µM and 
approximately 4:1 selectivity over the wild type protein (Figure 4.5). The mutant selectivity 
of hit 7b1 makes this compound an extremely promising initial candidate given the 
significance of this oncoprotein and the fact that no K-RasG12D-selective compounds have 
been reported to date.   
 
Second generation hits. In order to optimize hit 7b1 a second generation of compounds 
was synthesized based on rational modifications to the 7b1 variable region (Appendix A) 
– the sequences of the new compounds are listed in Table 4.2. The new PCC agent 
candidates were tested via single point ELISA assays and two new compounds of particular 
interest emerged – the compounds were identified as hits 7b5 and 7b10 (Figure 4.6).  
 
Characterization of ligand 7b10. From the single point ELISA assay of the new 
compounds hit 7b10 showed the greatest signal for K-RasG12D binding – this compound 
was therefore chosen for further characterization. Hit 7b10 was generated by replacing the 
arginine at position 5 in the variable region of 7b1 with the unnatural amino acid 4-
guanidine phenylalanine (Gnf),12 resulting in a new sequence of LRGD-Gnf. Hit 7b10 
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showed improved affinity of 17.5 µM for K-RasG12D and maintained 3:1 selectivity for 
the mutation over the wild type protein (Figure 4.7).  
 
In addition to assessing the binding properties of 7b10 we also sought to investigate any 
potential effects this compound may have on the GTPase activity of K-Ras. Ras sends 
downstream signals for cell growth and division when it is in the GTP-bound state. A 
potential Ras inhibitor would stimulate Ras enzymatic activity in order to promote GTP 
hydrolysis to GDP resulting in attenuation of the downstream signaling cascade. Indeed, 
when K-RasG12D complexed with a GTPase Activating Protein (GAP) was treated with 
7b10 the rate of GTP hydrolysis increased seven-fold relative to the wild type K-Ras-GAP 
complex (Figure 4.7C). Basal levels of K-Ras GTPase are very low so a GAP was added 
to enhance the signal to noise in the GTPase assay format. In addition to the novel mutant 
binding selectivity, 7b10 is also unique in its ability to restore Ras enzymatic activity as no 
such compounds has been reported. One possible explanation for the restoration of 
RAS/GAP GTPase activity is that the Gnf residue could be mimicking the GAP arginine 
finger that promotes the hydrolysis reaction. Normally GAPs stimulate Ras GTP hydrolysis 
by inserting an arginine residue, termed the arginine finger, near the GTP terminal 
phosphate that stabilizes the transition state of the hydrolysis reaction. Oncogenic Ras 
mutations at codons 12 and 13 are known to occlude the arginine finger from interacting 
with GTP through steric hindrance and thus render the protein GAP-insensitive.1 Perhaps 
the planar structure of the benzyl group in the Gnf side chain allows for insertion of the 
guanidium moiety into a productive GTPase-activating orientation. This important result 
warrants further investigation into the chemical mechanism of GTPase activation and 
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potential downstream K-Ras pathway inhibition in cells treated with 7b10. Stimulation 
of oncogenic K-Ras GTPase activity is expected to inhibit K-Ras signaling and validation 
of this result would demonstrate that 7b10 is a useful tool compound for perturbing 
oncogenic K-Ras signaling in cells.  
 
Understanding the binding of our PCC agent with K-RasG12D can provide guidance for 
rationally optimizing the PCC agent to improve its binding and functional properties. We 
next sought to identify the key interacting residues in 7b10 by conducting an alanine scan. 
A set of five new variants of 7b10 were synthesized with each compound presenting an 
alanine substation to one of residues in the variable region (Figure 4.8). If an alanine 
substation abrogates the affinity for K-Ras that would identify a potentially critical 
interacting residue. Conversely, if a residue can tolerate an alanine substitution and 
maintain its affinity for the target protein then that residue is likely not involved in binding. 
Indeed, the results from the alanine scan indicate that the only tolerable alanine substation 
is at aspartic acid at position four in the variable region. This result provides a logical path 
for 7b10 optimization. The aspartic acid at position four can potentially be replaced with 
another residue that does contribute to binding and improve the overall performance of the 
ligand. Alternatively, position four may also be a suitable branch point to screen for a 
secondary ligand in an additional in situ click screen.  
 
Characterization of ligand 7b5. Another interesting ligand identified in the second 
generation of hits was 7b5. This compound was generated by substituting the aspartic acid 
at position four of 7b1 with a proline resulting in a variable region of LRGDR (Figure 4.9). 
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However, this sequence did not stimulate K-Ras enzymatic activity when used in the 
GTPase assay — on the other hand, 7b5 appears to inhibit K-Ras (Figure 4.7C), which is 
the opposite of what is required for a potential K-Ras inhibitor. We hypothesized that 
substituting the anionic aspartic acid to the more hydrophobic proline residue could yield 
a cell-penetrant PCC agent — it is believed that peptides are more likely to be cell penetrant 
with cationic and/or hydrophobic residues.13 Compound 7b5 maintained an affinity of 56.6 
µM for K-RasG12D in spite of the proline substitution. Despite the lack of influence on Ras 
enzymatic activity (Figure 4.7C) this peptide could potentially be utilized as targeting 
ligand for PROTAC development, and indeed appears to reduce K-RasG12D expression on 
its own through an unknown mechanism (Figure 4.12).14 7b5 was synthesized with the 
HIF-1α degradation signal15 with and without a cell penetrating peptide (CPP) in order to 
test its performance as a potential K-Ras-PROTAC (Figures 4.10 and 4.11). The 
compounds were tested in the pancreatic carcinoma cell line Panc 08.13 because this cell 
line is known to be KRASG12D homozygous.16 When the cells were treated with the 7b5-
PROTACs a marked decrease in Ras protein was observed via western blot analysis. In 
order to test if the Ras degradation was mediated by the proteasome the experiment was 
repeated with an additional control. In the next experiment the cells were also pre-treated 
with the proteasome inhibitor MG13 before addition of the 7b5 PROTACs and the Ras 
degradation no longer occurred, supporting the notion that the 7b5-PROTAC is inducing 
proteasomal degradation of K-RasG12D (Figure 4.12). Surprisingly, in the second 
experiment unmodified 7b5 without the degradation tag appears to also decrease Ras 
expression (Figure 4.12B, lane 4). Speculatively, perhaps the hydrophobic glycine-proline 
sequence in 7b5 is causing the protein to misfold and undergo non-specific protesomal 
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degradation. Destabilization of the protein could be tested via a thermal denaturation 
assay to determine the melting temperature with and without the compound.  
 
4.4 Conclusion 
This work demonstrates the capacity of the PCC agent screening platform to develop 
ligands against difficult protein targets. Oncogenic K-Ras proteins were considered 
undruggable for many years and they still remain among the holy grails of cancer 
therapeutic targets.17 The epitope targeting strategy combined with the macrocyclic peptide 
library resulted in multiple ligands with previously undiscovered properties. Until now no 
ligand has been presented with selectivity for K-RasG12D oncoprotein but a single PCC 
agent screen has produced at least three such potential ligands. In addition, compound 7b10 
is the first known molecule to stimulate mutant K-Ras GTPase activity in in vitro 
biochemical assays. A future step towards characterizing compound 7b10 would be to test 
this result in cells through a RAS-GTP binding assay as well assessing downstream 
signaling pathway modulation. Finally, 7b5-PROTAC development is a promising 
approach to induced degradation of K-RasG12D in carcinoma cells. Unexpectedly, 
unmodified 7b5 also reduced K-Ras protein expression and it will be important to 
determine the mechanism of action in order to confirm the specificity of the compound 
towards K-Ras. While significant work must still be done to develop the first efficacious 
Ras inhibitors, this study presents proof of concept for two potential new strategies to target 
this difficult protein: enzymatic activation and targeted degradation.  
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4.5 Material and Methods 
Solid phase peptide synthesis general protocol 
Peptides were synthesized on Rink Amide MBHA or Biotin Novatag either by hand, on a 
Liberty1 Microwave Peptide Synthesizer (CEM), or on a Titan 357 Automatic Peptide 
Synthesizer (AAPPTec). Peptide coupling reactions were done in NMP with 2 
equivalents of amino acid, 2 equivalents of HATU, and 6 equivalents of N,N-
Diisopropylethylamine (Sigma). For removal of Nα-Fmoc protecting groups, a solution 
of 20% piperidine in NMP was used.  
 
Synthesis of K-Ras synthetic epitopes 
Modified K-Ras wild type and G12D epitopes were synthesized with acetylene-
functionalized amino acids for use in the in situ click screen (Figure 4.1).  The epitopes 
were derived from amino acids 2-22 from the K-Ras protein sequence with valine14 
substituted with propargylglycine (Pra).  Additionally, an 11-unit polyethylene glycol 
(PEG) spacer and biotin were added to the C-terminus of the synthesized fragments for 
detection with streptavidin during the screen. The sequence of the wild type K-Ras epitope 
fragment was NH2-TEYKLVVVGAGG[Pra]GK-PEG11-Biotin.  The sequence of the 
G12D fragment was NH2-TEYKLVVVGADG[Pra]GKSALTIQ-PEG11-Biotin.  The 
epitopes were synthesized by solid phase peptide synthesis (SPPS) on biotin novatag resin 
according to standard protocols. The peptides were removed from the resin and deprotected 
in a TFA cleavage solution of 95% TFA, 2.5% H2O, and 2.5% triethylsilane for two hours 
at room temperature. The cleavage solution was filtered to remove the resin and added 
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dropwise to an ice-cooled solution of diethyl ether to precipitate the crude peptide. Crude 
peptides were then purified via HPLC.  
 
Synthesis of macrocyclic peptides 
The macrocyclic peptides, including the library and hit sequences, were made by first 
synthesizing the linear sequence H2N-Pra-X1X2X3X4X5-Az4 via SPPS. On-bead Cu 
catalyzed click reactions were then performed to cyclize the peptide through the Pra and 
Az4 side chains. The resin was treated with 1.5 equivalents of CuI (Sigma) and 2.5 
equivalents of ascorbic acid (Sigma), in a solution of 20% piperidine in DMF. The reaction 
was performed overnight at room temperature. Excess copper was removed from the resin 
by washing with a Cu chelating solution (5% (w/v) sodium diethyl dithiocarbamate, 5% 
(v/v) DIEA in DMF). 
 
Synthesis of 7b5 PROTACs 
7b5-Hif and 7b5-Hif-TAT PROTACs that were used in the cell assays were made from 
previously-synthesized 7b5 peptide. After the 7b5 macrocycle was synthesized on resin 
Ahx was coupled to the N-terminus as a linker followed by the addition of the Hif-1α 
degradation sequence ALAPYIP using standard SPPS. The peptide was then either cleaved 
from the resin as 7b5-Hif (Figure 4.10) or the HIV-TAT sequence was added to create 7b5-
Hif-TAT (Figure 4.11). 
 
HPLC purification of peptides 
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All peptides were purified using a preparative or semi-preparative scale HPLC with a 
C18 reverse phase column. A gradient of double distilled water and HPLC grade 
acetonitrile and 0.1% TFA was used for all purifications. 
 
Mass spectrometry analysis 
All intermediate and final peptides were analyzed via MALDI-TOF-MS using a Voyager 
DE-PRO MALDI TOF-MS system (Applied Biosystems). Peptides were dissolved in 
50:50 water/acetonitrile with 0.1% trifluoroacetic acid at a final concentration of 10 
pmol/µL. 1 µL of the peptide sample was then added to 10 µL of a saturated solution of 
MALDI matrix, either α-cyano-4-hydroxycinnamic acid or Sinapinic Acid, in 50:50 
water/acetonitrile with 0.1% trifluoroacetic acid and analyzed via MALDI-TOF MS. 
 
Screening of KRAS Fragments to Identify Cyclic Anchors 
Preclear:  Approximately 500 mg (~1,400,000) beads of 5-mer macrocyclic peptide 
library (Figure 4.2) was obtained. The library sequence was Az4-[Pra]-X1X2X3X4X5-
[Az4]-M-TG where X = 18 amino acids (excluding Cys and Met) while [Pra] and [Az4] 
are connected via a 1,4-triazole linkage on tentagel resin (TG).  
 
Library was allowed to swell in TBS for 6 hours and then blocked overnight at 4 °C with 
1% BSA in TBS + 0.1% Tween 20 (= Blocking Buffer). The following day the library 
was washed with fresh blocking buffer and then incubated with 1:10,000 anti-Biotin-AP 
Antibody (Sigma Aldrich) in Blocking Buffer for 1 h at RT. Beads were then washed five 
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times with Blocking Buffer, five times with Wash 1 buffer (0.1% BSA in TBS + 0.1% 
Tween 20), and then five times with 3 mL Wash 2 buffer (TBS + 0.1% Tween 20). The 
preclear was then developed with BCIP: NBT (Promega #S3771).  The purple hit beads 
represent false hits that bind non-specifically to the anti-Biotin antibody and were thus 
removed.  
 
The remaining clear beads were washed with 7.5 M guanidine hydrochloride, pH 2.0 for 
30 min, then rinsed with water ten times. To remove residual purple color the clear beads 
were then incubated in NMP for two hours. After washing with water to remove the NMP 
the beads were blocked overnight at 4 °C with Blocking Buffer.  
 
Anti-screen against wild type K-Ras polypeptide target: The next day the precleared 
library was incubated with 50 µM (2% DMSO, v/v) wild type K-Ras fragment in 
blocking buffer for 5 hours at room temperature to allow the in situ click reaction to 
occur. The screen then proceeded as in the preclear above. Briefly, the beads were 
washed, stripped in 7.5 M guanidine hydrochloride, washed, blocked, probed with anti-
Biotin-AP, and developed with BCIP/NBT. Approximately 200 purple hits were 
identified that represent library elements that bound to the wild type K-Ras fragment. 
After removal of the purple beads the library was again decolorized and blocked 
overnight in preparation for the target screen with the G12D epitope.  
 
Product screen against the mutant K-RasG12D fragment: The next day the precleared 
and anti-screened library was incubated with the mutant polypeptide target. 25 µM G12D 
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fragment was incubated with the library to undergo a second in situ click reaction, this 
time against the desired target. The library was then probed and developed as before and 
7 hit beads were identified. Hit beads were then sequenced via Edman degradation and 
the results are shown in Table 4.1.  
 
Protein expression and purification.  
His-tagged human K-RasG12D (isoform 4B) GTPase domain (residues 1-169) was 
transformed into E. coli BL21(DE3) cells. Bacterial cultures were grown in LB broth 
with ampicillin until the OD600 reached approximately 0.5. Expression was induced with 
0.5 mM IPTG at 18°C for about 18 hours overnight and cells were harvested by 
centrifugation and pellets were stored at -80°C.  
 
  Cell pellets were suspended in 20 mM Tris, pH 8.0 with 500 mM NaCl, 5 mM 
imidazole and 1 mM DTT. Cells were then lysed by microfluidizer and cellular debris 
was removed by ultracentrifugation. Crude lysate was then passed through a 0.22 µm 
filter and purified with a Ni-NTA column and eluted with an imidazole gradient. K-
RasG12D fractions were then pooled and then buffer exchanged into 20 mM HEPES, pH 
7.5, 150 mM NaCl, and 1 mM DTT using a HiTrap desalting column. Protein was the 
purified by gel filtration with a Superdex 75 column and pure protein was aliquoted and 
flash frozen in liquid nitrogen and thawed as needed.  
 
ELISA of hit peptides against full-length K-Ras protein 
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1 µM of the biotinylated hit peptides were first immobilized onto 96-well Neutravidin 
ELISA plates (Pierce) for 2 hours at room temperature in binding buffer: Tris-buffered 
saline TBS with 0.1% Tween-20 (TBST) and 0.1% BSA. The plates were then blocked 
with 5% BSA in TBST for 1 hour, followed by incubating with full-length K-Ras protein 
in binding buffer for 30 minutes. For single point ELISA assays 100 nM K-Ras protein 
was added per well. For EC50 determination the protein was added at various 
concentrations. After washing three times with TBST the plate was then treated with a 
1:1000 dilution of the anti-RAS rabbit mAb (Cell Signaling Technology) in binding buffer 
for thirty minutes, washed three times with TBST, incubated with anti-Rabbit-HRP 
secondary antibody (Cell Signaling Technology) for thirty minutes, and developed with 
TMB substrate (KPL) for five to ten minutes. The absorbance of samples at 450 nm 
wavelength was measured using a FlexStation 3 microplate reader (Molecular Devices).  
 
K-Ras GTPase assay 
To assess the effects of compound 7b10 and 7b5 on K-Ras enzymatic activity a GTPase 
assay kit (Sigma #MAK113-1KT) was used. Recombinant K-Ras protein was combined 
with the recombinant human protein RAS GTPase Activating Protein Protein 1 
(MyBiosource #MBS951091) to enhance the activity to detectable levels. In a 96-well plate 
20 µL of 0.7 mg/mL K-Ras protein (0.6 nmol) was combined with 1 µL of 0.1 mg/mL 
RasGAP1, 5 µL of 100 µM peptide (7b5 or 7b10), 20 µL reaction buffer (20 mM HEPES 
pH = 7.5, 150 mM NaCl, 1 mM DTT, 20 mM MgCl2), and 10 µL of 4 mM GTP and the 
reaction was allowed to proceed at room temperature for 30 minutes followed by the 
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addition of the 200 µL malachite green reagent (Sigma) and the absorbance was 
measured at 620 nm.  
 
 
Cell Culture 
Panc 08.13 cells were purchased from American Type Culture collection (Manassas, VA, 
USA) and cultured under conditions specified by the provider. 
 
Immunoblotting 
Western blots were performed according to standard protocols. Briefly, cells were lysed 
with cell lysis buffer (Cell Signaling Technology) containing protease and phosphatase 
inhibitors (Cell Signaling Technology). Cell lysates were quantified with a Bradford 
protein assay (Thermo Scientific, Waltham, MA, USA) and prepared for gel 
electrophoresis in Laemmli sample buffer and reducing agent. Twenty micrograms of cell 
lysate were added to precast polyacrylamide gels (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA), and proteins were separated by electrophoresis followed by transfer to PVDF 
membrane. Membranes were then blocked and probed with primary antibodies followed 
by horseradish peroxidase-conjugated secondary antibodies. The bands were visualized 
via a chemiluminescent substrate (Thermo Scientific). Ras and tubulin antibodies were 
from Cell Signaling Technology and used according to manufacturer protocol.   
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4.6 Figures 
 
  
Figure 4.1 – Structure of K-Ras synthetic epitopes. (A) The structure of the wild type K-Ras 
epitope that was used in the anti-screen. The epitope consists of K-Ras residues 2-20 with a 
V14Pra substitution for the in situ click reaction.  (B) The molecular structure of the K-Ras
G12D
 
epitope used in the target screen. The epitope consists of K-Ras residues 2-20 with the G12D 
mutation and V14Pra substitution for the in situ click reaction.  
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Figure 4.2 – Structure of the macrocyclic peptide library.  
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Figure 4.3 – Layout of the K-Ras epitope-targeted PCC agent screen. A 1.4x10
6 
member macrocyclic 
library was first anti-screened against the wild type K-Ras sequence corresponding to residues 2-20. 
Approximately 200 hit peptides reacted with the wild type epitope and were removed. The remaining 
beads were then incubated with the G12D fragment, resulting in 7 hit beads.  
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 Variable region 
Sequence X1 X2 X3 X4 X5 
1 N D E T Y 
2 P S E E G 
3 S E E G G 
4 E G T G T 
5 Y E Q G E 
6 Y G E Q E 
7 L R G D R 
8 Q E K P P 
9 E L T F G 
Table 4.1 – Hit sequences from K-Ras
G12D 
epitope-targeted anchor screen. The 
seven hit beads produced nine possible sequences. Sequences 2 and 3, as well as 5 and 
6, represent multiple possible sequences from a single hit bead.  
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Figure 4.4 – Single point ELISA of hit peptides against K-Ras
G12D
 
protein. The hit peptides were tested against the full-length mutant protein. 
Several sequences produced multiple isobaric fractions after HPLC 
purification.  
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Figure 4.5 – Characterization of hit 7b1. (A) Molecular structure of hit 7b1 from the initial 
anchor screen. (B) Binding curve between hit 7b1 and K-Ras
G12D
 obtained via ELISA assay. (C) 
A single point ELISA assay assessing the selectivity of 7b1 for wild type vs. G12D K-Ras. The 
peptide shows an approximately 4:1 selectivity for the mutant protein.  
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 Sequence 
Peptide  X1 X2 X3 X4 X5  
7b1 Pra L R G D R Az4 
7b2 Az4 L R G D R Pra 
7b3 Pra L R G D R Az3 
7b4 Pra V R G D R Az4 
7b5 Pra L R G P R Az4 
7b6 Pra L R G E R Az4 
7b7 Pra L homo-Arg G D R Az4 
7b8 Pra L R G D homo-Arg Az4 
7b9 Pra L Gnf G D R Az4 
7b10 Pra L R G D Gnf Az4 
7b11 Pra L R G N R Az4 
7b12 Pra L R G Q R Az4 
Table 4.2 – Sequences of second generation of hits designed from hit 7b1. Members of the new series of 
compounds contained the unnatural amino acids homoarginine (homo-Arg) or 4-guanidine 
phenylalanine (Gnf). 
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Figure 4.6 – Single point ELISA of second generation hits K-Ras
G12D
.  
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Figure 4.7 – Characterization of hit 7b10. (A) Molecular structure of hit 7b10. (B) Binding 
curve between hit 7b10 and K-Ras wild type and G12D obtained via ELISA assay. The peptide 
EC
50 
= 17.5 µM for K-Ras
G12D
 and EC
50 
= 55.6 µM for wild type K-Ras.(C) 7b10 increases wild 
type and G12D K-Ras GTPase activity nearly seven-fold.  
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Figure 4.8 – 7b10 alanine scan. (A) Sequences of alanine-substituted peptide series (B) Binding 
curves between alanine scan peptides and K-Ras
G12D
 obtained via ELISA assay. Only peptide A4 
maintains binding affinity for K-Ras
G12D
.  
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Figure 4.9 – Characterization of hit 7b5. (A) Molecular structure of hit 7b5. (B) Binding curve 
between hit 7b5 and K-Ras
G12D
 obtained via ELISA assay. The peptide EC
50 
= 56.6 µM for K-
Ras
G12D
.  
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Figure 4.10 – Structure of 7b5-Hif PROTAC.  
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Figure 4.12 – 7b5 PROTACs induce proteasomal degradation of K-RasG12D. (A) 
Western blot of lysates from Panc 08.13 cells treated with either 7b5, 7b5-Hif, or 7b5-Hif-
TAT. Cells were treated for 4 hours prior to lysis. (B) Western blot of lysates from Panc 
08.13 cells treated with 0.3 mM 7b5, 7b5-Hif, or 7b5-Hif-TAT. Cells were also pretreated 
with the proteasome inhibitor MG132 and the Ras degradation was reversed.  
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A p p e n d i x  A  
SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
A.1 Structure and Characterization of Synthetic Epitopes used in Anchor Screen 
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A.2 Structure and Characterization of Hit Peptides from Anchor Screen 
  
Figure A3 – Structure and characterization of hit 1: NDETY. MALDI-TOF MS: 
Expected [M+H]
+
 = 1159.26, Observed [M+H]
+
 = 1158.  
Hit 1: Pra-NDETY-Az4-Biotin 
  
93 
 
  
Hit 2: Pra-PSEEG-Az4-Biotin 
Figure A4 – Structure and characterization of hit 2: PSEEG. MALDI-TOF MS: 
Expected [M+H]
+
 = 1036.15, Observed [M+H]
+
 = 1035.  
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Hit 3: Pra-SEEGG-Az4-Biotin 
Figure A5 – Structure and characterization of hit 3: SEEGG. MALDI-TOF MS: 
Expected [M+H]
+
 = 996.08, Observed [M+H]
+
 = 995.8.  
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5 = YEQGE 
Hit 5: Pra-YEQGE-Az4-Biotin 
Figure A6 – Structure and characterization of hit 5: YEQGE. MALDI-TOF MS: 
Expected [M+H]
+
 = 1143.26, Observed [M+H]
+
 = 1142.  
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6 = YGEQE 
Hit 6: Pra-YGEQE-Az4-Biotin 
Figure A7 – Structure and characterization of hit 6: YGEQE. MALDI-TOF MS: 
Expected [M+H]
+
 = 1143.26, Observed [M+H]
+
 = 1142.  
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7 - LRGDR 
Hit 7: Pra-LRGDR-Az4-Biotin 
Figure A8 – Structure and characterization of hit 7: LRGDR. MALDI-TOF MS: 
Expected [M+H]
+
 = 1134.35, Observed [M+H]
+
 = 1134.  
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8 = QEKPP 
Hit 8: Pra-QEKPP-Az4-Biotin 
Figure A9 – Structure and characterization of hit 8: QEKPP. MALDI-TOF MS: 
Expected [M+H]
+
 = 1116.32, Observed [M+H]
+
 = 1116.  
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9 = ELTFG 
Hit 9: Pra-ELTFG-Az4-Biotin 
Figure A10 – Structure and characterization of hit 9: ELTFG. MALDI-TOF MS: 
Expected [M+H]
+
 = 1084.28, Observed [M+H]
+
 = 1084.  
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A.3 STRUCTURE AND CHARACTERIZATION OF SECOND 
GENERATION HIT PEPTIDES 
  
7b1: Pra-LRGDR-Az4-PEG
5
-Biotin 
m/z 
Figure A11 - Structure and characterization of peptide 7b1. The peptide sequence is 
Pra-LRGDR-Az4-PEG5-Biotin with a 1,4-triazole linkage between Pra and Az4. MALDI-
TOF MS: Expected [M+H]
+
 = 1294.6, Observed [M+H]
+ 
= 1292.9 
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7b2: Az4-LRGDR-Pra-PEG
5
-Biotin 
m/z 
Figure A12 - Structure and characterization of peptide 7b2. The peptide sequence 
is Az4-LRGDR-Pra-PEG
5
-Biotin with a 1,4-triazole linkage between Az4 and Pra. 
MALDI-TOF MS: Expected [M+H]
+
 = 1294.6, Observed [M+H]
+ 
= 1293.1 
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  7b3: Pra-LRGDR-Az3-PEG
5
-Biotin 
m/z 
Figure A13 - Structure and characterization of peptide 7b3. The peptide 
sequence is Pra-LRGDR-Az3-PEG
5
-Biotin with a 1,4-triazole linkage between 
Pra and Az3. MALDI-TOF MS: Expected [M+H]
+
 = 1280.5, Observed [M+H]
+ 
= 1278.9 
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7b4: Pra-VRGDR-Az4-PEG
5
-Biotin 
m/z 
Figure A14 - Structure and characterization of peptide 7b4. The peptide sequence is Pra-VRGDR-Az4-
PEG
5
-Biotin with a 1,4-triazole linkage between Pra and Az4. MALDI-TOF MS: Expected [M+H]
+
 = 
1280.5, Observed [M+H]
+ 
= 1279.3 
  
104 
 
  
7b5: Pra-LRGPR-Az4-PEG
5
-Biotin 
m/z 
Figure A15 - Structure and characterization of peptide 7b5. The peptide sequence is Pra-
LRGPR-Az4-PEG
5
-Biotin with a 1,4-triazole linkage between Pra and Az4. MALDI-TOF 
MS: Expected [M+H]
+
 = 1276.6, Observed [M+H]
+ 
= 1275.0 
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7b6: Pra-LRGER-Az4-PEG
5
-Biotin 
m/z 
Figure A16 - Structure and characterization of peptide 7b6. The 
peptide sequence is Pra-LRGER-Az4-PEG
5
-Biotin with a 1,4-
triazole linkage between Pra and Az4. MALDI-TOF MS: Expected 
[M+H]
+
 = 1308.6, Observed [M+H]
+ 
= 1307.1 
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7b7: Pra-Leu-Homoarginine-Gly-Asp-Arg-Az4-PEG
5
-Biotin 
m/z 
Figure A17 - Structure and characterization of peptide 7b7. The peptide 
sequence is Pra-L[Homoarginine]GDR-Az4-PEG
5
-Biotin with a 1,4-triazole 
linkage between Pra and Az4. MALDI-TOF MS: Expected [M+H]
+
 = 1308.6, 
Observed [M+H]
+ 
= 1307.0 
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  7b8: Pra-Leu-Arg-Gly-Asp-Homoarginine-Az4-PEG
5
-Biotin 
m/z 
Figure A18 - Structure and characterization of peptide 7b8. The 
peptide sequence is Pra-LRGD[Homoarginine]-Az4-PEG
5
-Biotin with a 
1,4-triazole linkage between Pra and Az4. MALDI-TOF MS: Expected 
[M+H]
+
 = 1308.6, Observed [M+H]
+ 
= 1307.0 
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  7b9: Pra-Leu-Guanidinophenylalanine-Gly-Asp-Arg-Az4-PEG5-Biotin 
m/z 
Figure A19 - Structure and characterization of peptide 7b9. The peptide sequence is Pra-
L[Guanidinophenylalanine]GDR-Az4-PEG
5
-Biotin with a 1,4-triazole linkage between Pra 
and Az4. MALDI-TOF MS: Expected [M+H]
+
 = 1342.6, Observed [M+H]
+ 
= 1342.5 
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7b10: Pra-Leu-Arg-Gly-Asp-Guanidionphenylalanine-Az4-PEG
5
-Biotin 
m/z 
Figure A20 - Structure and characterization of peptide 7b10 .The peptide sequence is Pra-
LRGD[Guanidinophenylalanine] -Az4-PEG
5
-Biotin with a 1,4-triazole linkage between Pra and Az4. 
MALDI-TOF MS: Expected [M+H]
+
 = 1342.6, Observed [M+H]
+ 
= 1341.3 
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7b11: Pra-LRGNR-Az4-PEG
5
-Biotin 
m/z 
Figure A21 - Structure and characterization of peptide 7b11. The peptide sequence is Pra-LRGNR-Az4-
PEG
5
-Biotin with a 1,4-triazole linkage between Pra and Az4. MALDI-TOF MS: Expected [M+H]
+
 = 
1293.6, Observed [M+H]
+ 
=  1291.7 
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 7b12: Pra-LRGQR-Az4-PEG
5
-Biotin 
m/z 
Figure A22 - Structure and characterization of peptide 7b12. The peptide sequence is Pra-LRGQR-Az4-
PEG
5
-Biotin with a 1,4-triazole linkage between Pra and Az4. MALDI-TOF MS: Expected [M+H]
+
 = 1307.6, 
Observed [M+H]
+ 
=  1306.2 
